Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Tuberculosis and pregnancy].

B Dautzenberg1, J Grosset

  • 1G.H. Pitié-Salpêtrière, Paris.

Revue Des Maladies Respiratoires
|January 1, 1988
PubMed
Summary
This summary is machine-generated.

Tuberculosis treatment during pregnancy is safe with a specific drug regimen. Careful management minimizes risks to both mother and child, allowing for breastfeeding.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Deleterious effects of heated tobacco on respiratory symptoms and lung function].

Revue des maladies respiratoires·2024
Same author

Revue des maladies respiratoires actualites·2021
Same author

Transdermal nicotine in non-smokers: A systematic review to design COVID-19 clinical trials.

Respiratory medicine and research·2021
Same author

Multidisciplinary advisory teams to manage multidrug-resistant tuberculosis: the example of the French Consilium.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2019
Same author

[Systematic analysis of the scientific literature on heated tobacco].

Revue des maladies respiratoires·2018
Same author

[Old and new tobacco products].

Revue de pneumologie clinique·2018
Same journal

[French version of the guidelines for connective tissue disease-associated ILD].

Revue des maladies respiratoires·2026
Same journal

[Pulmonary expression of an asymptomatic lysosomal storage disorder].

Revue des maladies respiratoires·2026
Same journal

[Factors associated with FEV1 evolution in cystic fibrosis patients treated by CFTR modulator tritherapy].

Revue des maladies respiratoires·2026
Same journal

[Subacute pulmonary coccidioidomycosis: A differential diagnosis of lung cancer].

Revue des maladies respiratoires·2026
Same journal

[Relevance of the ACT score in severe asthma with obesity: A pilot study].

Revue des maladies respiratoires·2026
Same journal

[Automated analysis of mandibular movements for the screening of obstructive sleep apnea].

Revue des maladies respiratoires·2026
See all related articles

Area of Science:

  • Obstetrics and Gynecology
  • Infectious Diseases
  • Pharmacology

Context:

  • Tuberculosis (TB) incidence and severity are similar in pregnant and non-pregnant women.
  • Pregnancy presents unique risks for TB: increased maternal mortality if untreated, drug toxicity, and perinatal infection.
  • Maternal TB poses significant risks to the fetus and newborn.

Purpose:

  • To outline safe and effective tuberculosis treatment protocols for pregnant women.
  • To detail drug choices, dosages, and treatment durations during pregnancy.
  • To provide guidelines for newborn care, including chemoprophylaxis and BCG vaccination.

Summary:

  • Tuberculosis in pregnancy requires a tailored approach, utilizing isoniazid, ethambutol, and rifampicin.
  • Isoniazid and ethambutol have low toxicity; rifampicin is used cautiously, especially in the first trimester.

Related Experiment Videos

  • Pyrazinamide is contraindicated in pregnancy due to insufficient safety data.
  • Treatment involves a 9-month regimen of rifampicin and isoniazid, with ethambutol for two months.
  • Newborns require isoniazid chemoprophylaxis until maternal smear microscopy is negative, followed by BCG vaccination.
  • Breastfeeding is permissible with appropriate maternal treatment, as minimal drug transfer occurs in breast milk.

    • Impact:

    • Ensures optimal maternal health outcomes for pregnant women with tuberculosis.
    • Reduces the risk of congenital tuberculosis and neonatal mortality.
    • Facilitates safe mother-infant bonding and continued breastfeeding.
    • Provides evidence-based guidance for clinicians managing tuberculosis in pregnancy.